1.A Case of Extraskeletal Myxoid Chondrosarcoma of Pelvic cavity.
Hyun Ju CHO ; Ick Doo KIM ; Ho Jin CHAE ; Jung Sil PARK ; Kook Hwan BAE
Korean Journal of Obstetrics and Gynecology 2005;48(8):1982-1987
Chondrosarcoma is an extremely rare cause of pelvic mass mimicking ovarian carcinoma. Imaging techniques, even CT and MRI, failed to define the exact origin of the tumor. These findings as well as the elevated CA-125 level naturally resulted in a preoperative diagnosis of ovarian carcinoma. Surgical removal is the most important treatment of choice for chondrosarcoma. We experienced a case of extraskeletal myxoid chondrosarcoma of pelvic cavity in a 45-year-old patient, who presented with abdominal distension and lower abdominal palpable mass, and reported it with a brief review of literatures.
Chondrosarcoma*
;
Diagnosis
;
Humans
;
Magnetic Resonance Imaging
;
Middle Aged
2.Complete Resolution of Posttransplant Lymphoproliferative Disorder (Diffuse Large B-cell Lymphoma) with Reduction of Immunosuppressive Therapy.
Han Jak RYU ; Jee Sook HAHN ; Yu Seun KIM ; Kiil PARK ; Woo Ick YANG ; Jong Doo LEE
Yonsei Medical Journal 2004;45(3):527-532
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation. PTLD is the disorder arising from the combined effects of Epstein-Barr virus associated lymphoid proliferation with the disruption of the normal immune control by the cytotoxic T cells. The treatment for PTLD is one of the most controversial topics in solid organ transplantation. It is well known that the initial management of PTLD is a reduction of immunosuppression. Early diagnosis and the early reduction in immunosuppression are essential even for monomorphic lymphoma. We report here on a case of the complete resolution of PTLD (diffuse large B cell lymphoma) which occurred after a drastic reduction of immunosuppression in a renal transplant recipient.
Adult
;
Graft Rejection/*drug therapy
;
Human
;
Immunosuppressive Agents/*administration & dosage
;
*Kidney Transplantation
;
Korea
;
Lymphoma, Large-Cell, Diffuse/*drug therapy/radiography/radionuclid imaging
;
Male
;
Remission Induction
;
Tomography, Emission-Computed
;
Tomography, X-Ray Computed
3.Detection of tuberculous lesion by immunoscintigraphy using radiolabeled specific polyclonal antibody against M. bovis in rabbit: apreliminary result.
Jong Doo LEE ; Kyoo Ho SHIN ; Sang Nae CHO ; Jeon Soo SHIN ; Min Geol LEE ; Woo Ick YANG ; Chang Yoon PARK ; Hyung Sik YOO ; Jong Tae LEE ; Ok Doo AWH ; Kyung Bae PARK ; Jae Rok KIM
Korean Journal of Nuclear Medicine 1991;25(2):245-251
No abstract available.
4.A Case of Primary Non-Hodgkin's Lymphoma of the Ovary.
Chang Soo YOON ; Hyun Ju CHO ; Ick Doo KIM ; Jung Sil PARK ; Kwang Soo HAN ; Kook Hwan BAE ; Ho Kyun KIM
Korean Journal of Obstetrics and Gynecology 2004;47(11):2246-2250
Primary non-Hodgkin's lymphoma of the ovary is a rare ovarian malignancy. Previous reports of ovarian non-Hodgkin's lymphoma have included both primary and secondary cases, because exactly defined criteria was not available. Ovarian lymphoma has been reported poor prognosis. However, true primary ovarian lymphoma shows a favorable prognosis. We experienced a case of primary non-Hodgkin's lymphoma of the ovary in a 34-year-old patient, who presented with abdominal distension and abdominal pain, and reported it with a brief review of literatures.
Abdominal Pain
;
Adult
;
Female
;
Humans
;
Lymphoma
;
Lymphoma, Non-Hodgkin*
;
Ovary*
;
Prognosis
5.Expression of p63 and its Isoform, deltaNp63, in Non-Small Cell Lung Carcinoma.
Ick Doo KIM ; Dong Hoon SHIN ; Kyung Un CHOI ; Do Youn PARK ; Gi Yeong HUH ; Mee Young SOL ; Min Ki LEE ; Young Dae KIM ; Chang Hun LEE
Korean Journal of Pathology 2009;43(4):321-328
BACKGROUND: Several studies have been conducted on the role of the p63 gene family in non-small cell lung carcinoma (NSCLC). Nevertheless, the role of these genes in the development and progression of NSCLC remains controversial. This study was designed to examine the expression and clinicopathologic significance of the p63 family in NSCLC. METHODS: Immunohistochemical staining was performed on 92 cases of NSCLC (47 squamous cell carcinomas [SqCCs] and 45 adenocarcinomas [ACs]) using tissue microarray blocks. The results were analyzed and correlated with clinicopathologic data. RESULTS: The expression of delta Np63 (Delta Np63) was elevated in SqCC (39/47), but not in AC (2/45; p<0.01). Both p63 and Delta Np63 had high expression in 39 SqCCs; p63 and Delta Np63 also had a similar geomorphologic distribution in most positive tumors. The expression of Delta Np63 was correlated with histologic type, gender, pT stage, p53 expression, and p63 expression. pT and pN stages were independent factors in survival (p<0.05, respectively). CONCLUSIONS: The major p63 isoform in NSCLC, Delta Np63, had a strong correlation with p53 and p63, and was exclusively expressed in SqCC. However, our findings suggest that Delta Np63 was not an independent prognostic factor for NSCLC.
Adenocarcinoma
;
Carcinoma, Non-Small-Cell Lung
;
Carcinoma, Squamous Cell
;
Humans
;
Immunohistochemistry
;
Lung
6.Fine Needle Aspiration Cytology of Palpable Lymph Nodes: A Single Institutional Experience of 1,346 Cases.
Dong Hoon SHIN ; Kyung Un CHOI ; Jee Yeon KIM ; Hyun Jeong KANG ; Ick Doo KIM ; Mee Young SOL
Korean Journal of Cytopathology 2007;18(2):126-132
The aim of this study was to evaluate the diagnostic value of fine needle aspiration cytology (FNAC) for the assessment of palpable enlarged lymph nodes. The authors reviewed the results of 1,346 FNACs of palpable enlarged lymph nodes performed at Pusan National University Hospital from 1998 to 2004. Of the 1,346 cases, 1,265 (94.0%) were satisfactory and 81 (6.0%) unsatisfactory. Cytologic diagnoses were judged in 488 cases, based on subsequent histologic diagnoses, clinical follow up, or both. Global results for all malignancies (lymphoid and non-lymphoid neoplasms) based on cases with final diagnoses, showed a sensitivity of 87.4% and a specificity of 98.7%. The overall diagnostic accuracy was 93.2%, and the false negative rate reduced from 12.6% to 7.3% when lymphomatous cases were excluded. The annual data for this period showed that the number of diagnostic lymph node biopsies and the rate of inadequately sampled material markedly decreased. Gene rearrangement studies for IgH and TCR gamma were helful in 30 cases. FNAC is a useful initial diagnostic procedure for the evaluation of palpable enlarged lymph nodes. However, the technique should be assisted by the appropriate ancillary studies and by proper interpretation by a cytopathologist.
Biopsy
;
Biopsy, Fine-Needle*
;
Busan
;
Diagnosis
;
Follow-Up Studies
;
Gene Rearrangement
;
Lymph Nodes*
;
Sensitivity and Specificity
7.Validity and Reliability of the Korean Version of the Hamilton Depression Rating Scale(K-HDRS).
Jung Seo YI ; Seung Oh BAE ; Yong Min AHN ; Doo Byoung PARK ; Kyung Sun NOH ; Hyun Kyun SHIN ; Haing Won WOO ; Hong Shick LEE ; Sang Ick HAN ; Yong Sik KIM
Journal of Korean Neuropsychiatric Association 2005;44(4):456-465
OBJECTIVES: The reliability and validity of the Korean version of Hamilton Depression Rating Scale (K-HDRS) were examined in Korean patients depressive symptoms. METHODS: 33 inpatients and 70 outpatients diagnosed as major depressive disorder or depressive episode of bipolar I disorder according to the DSM-IV criteria were assessed with K-HDRS, Clinical Global Impression score(CGI), Beck Depression Inventory (BDI) and Montgomery-Aberg Depression Rating Scale (MADRS). RESULTS: Internal consistency (Cronhach's alpha coefficeint=0.76) and interrater reliability (r=0.94, p<0.001) were statistically significant. Principal axis factoring analysis revealed 4 factors that accounted for 50.4% of the total variance. The correlations of K-HDRS with CGI, BDI and MADRS were 0.84, 0.54, 0.58 respectively. CONCLUSION: These results showed that the K-HDRS could be a reliable and valid tool for the assessment of depressive Korean patients. The K-HDRS will be a useful tool for assessing depressive symptoms in Korea.
Axis, Cervical Vertebra
;
Depression*
;
Depressive Disorder, Major
;
Diagnostic and Statistical Manual of Mental Disorders
;
Humans
;
Inpatients
;
Korea
;
Outpatients
;
Reproducibility of Results*
8.Mortality of Community-Acquired Pneumonia in Korea: Assessed with the Pneumonia Severity Index and the CURB-65 Score.
Hye In KIM ; Shin Woo KIM ; Hyun Ha CHANG ; Seung Ick CHA ; Jae Hee LEE ; Hyun Kyun KI ; Hae Suk CHEONG ; Kwang Ha YOO ; Seong Yeol RYU ; Ki Tae KWON ; Byung Kee LEE ; Eun Ju CHOO ; Do Jin KIM ; Cheol In KANG ; Doo Ryeon CHUNG ; Kyong Ran PECK ; Jae Hoon SONG ; Gee Young SUH ; Tae Sun SHIM ; Young Keun KIM ; Hyo Youl KIM ; Chi Sook MOON ; Hyun Kyung LEE ; Seong Yeon PARK ; Jin Young OH ; Sook In JUNG ; Kyung Hwa PARK ; Na Ra YUN ; Sung Ho YOON ; Kyung Mok SOHN ; Yeon Sook KIM ; Ki Suck JUNG
Journal of Korean Medical Science 2013;28(9):1276-1282
The pneumonia severity index (PSI) and CURB-65 are widely used tools for the prediction of community-acquired pneumonia (CAP). This study was conducted to evaluate validation of severity scoring system including the PSI and CURB-65 scores of Korean CAP patients. In the prospective CAP cohort (participated in by 14 hospitals in Korea from January 2009 to September 2011), 883 patients aged over 18 yr were studied. The 30-day mortalities of all patients were calculated with their PSI index classes and CURB scores. The overall mortality rate was 4.5% (40/883). The mortality rates per CURB-65 score were as follows: score 0, 2.3% (6/260); score 1, 4.0% (12/300); score 2, 6.0% (13/216); score 3, 5.7% (5/88); score 4, 23.5% (4/17); and score 5, 0% (0/2). Mortality rate with PSI risk class were as follows: I, 2.3% (4/174); II, 2.7% (5/182); III, 2.3% (5/213); IV, 4.5% (11/245); and V, 21.7% (15/69). The subgroup mortality rate of Korean CAP patients varies based on the severity scores and CURB-65 is more valid for the lower scores, and PSI, for the higher scores. Thus, these variations must be considered when using PSI and CURB-65 for CAP in Korean patients.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Asian Continental Ancestry Group
;
Cohort Studies
;
Community-Acquired Infections/*mortality
;
Female
;
Humans
;
Intensive Care Units
;
Male
;
Middle Aged
;
Pneumonia/*mortality
;
Prospective Studies
;
Republic of Korea
;
*Severity of Illness Index
;
Young Adult
9.Efficacy and Safety Profile of Risperidone in Schizophrenia: Open Multicenter Clinical Trial.
Min Soo LEE ; Yong Ku KIM ; Young Hoon KIM ; Byeong Kil YEON ; Byoung Hoon OH ; Doh Joon YOON ; Jin Sang YOON ; Chul LEE ; Hee Yeon JEOUNG ; Byung Jo KANG ; Kwang Soo KIM ; Dong Eon KIM ; Myung Jung KIM ; Sang Hun KIM ; Hee Cheol KIM ; Chul NA ; Seung Ho RHO ; Kyung Joon MIN ; Ki Chang PARK ; Doo Byung PARK ; Ki Chung PAIK ; In Ho PAIK ; Bong Ki SON ; Jin Wook SOHN ; Byung Hwan YANG ; Chang Kook YANG ; Haing Won WOO ; Jung Ho LEE ; Jong Bum LEE ; Hong Shick LEE ; Ki Young LIM ; Tae Youn JUN ; Young Cho CHUNG ; Young Chul CHUNG ; In Kwa JUNG ; In Won CHUNG ; Ik Seung CHEE ; Jeong Ho CHAE ; Sang Ick HAN ; Sun Ho HAN ; Jin Hee HAN ; Kwang Yoon SUH
Journal of Korean Neuropsychiatric Association 1998;37(1):60-74
OBJECTIVE: The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. METHOD: This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points: at baseline, and 1,2,4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. RESULTS: 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action: a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. CONCLUSIONS: This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.
Dyskinesias
;
Dystonia
;
Electrocardiography
;
Hospitalization
;
Hospitals, University
;
Humans
;
Parkinsonian Disorders
;
Risperidone*
;
Schizophrenia*
;
Vital Signs
;
Weights and Measures